- Home
- TVGN vs RCEL Comparison
TVGN vs RCEL Comparison
Compare TVGN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- RCEL
- Stock Information
- Founded
- TVGN 2020
- RCEL N/A
- Country
- TVGN United States
- RCEL United States
- Employees
- TVGN N/A
- RCEL N/A
- Industry
- TVGN Blank Checks
- RCEL Medical/Dental Instruments
- Sector
- TVGN Finance
- RCEL Health Care
- Exchange
- TVGN Nasdaq
- RCEL Nasdaq
- Market Cap
- TVGN 198.6M
- RCEL 227.5M
- IPO Year
- TVGN N/A
- RCEL N/A
- Fundamental
- Price
- TVGN $0.98
- RCEL $9.21
- Analyst Decision
- TVGN Strong Buy
- RCEL Strong Buy
- Analyst Count
- TVGN 1
- RCEL 4
- Target Price
- TVGN $10.00
- RCEL $17.25
- AVG Volume (30 Days)
- TVGN 528.6K
- RCEL 201.7K
- Earning Date
- TVGN 05-28-2025
- RCEL 05-08-2025
- Dividend Yield
- TVGN N/A
- RCEL N/A
- EPS Growth
- TVGN N/A
- RCEL N/A
- EPS
- TVGN N/A
- RCEL N/A
- Revenue
- TVGN N/A
- RCEL $64,251,000.00
- Revenue This Year
- TVGN N/A
- RCEL $62.33
- Revenue Next Year
- TVGN N/A
- RCEL $30.59
- P/E Ratio
- TVGN N/A
- RCEL N/A
- Revenue Growth
- TVGN N/A
- RCEL 28.14
- 52 Week Low
- TVGN $0.26
- RCEL $6.90
- 52 Week High
- TVGN $3.09
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- TVGN 40.84
- RCEL 56.76
- Support Level
- TVGN $0.93
- RCEL $8.15
- Resistance Level
- TVGN $1.13
- RCEL $9.36
- Average True Range (ATR)
- TVGN 0.11
- RCEL 0.67
- MACD
- TVGN 0.00
- RCEL 0.15
- Stochastic Oscillator
- TVGN 25.00
- RCEL 93.90
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.